Travere Therapeutics (TVTX) Other Non-Current Liabilities (2011 - 2026)

Travere Therapeutics' Other Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $9.4 million for Q1 2026.

• Quarterly Other Non-Current Liabilities rose 28.92% year-over-year to $9.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (up 28.92% YoY) and the FY2025 annual result came in at $7.6 million, up 11.85% from the prior year.
• Other Non-Current Liabilities was $9.4 million for Q1 2026 at Travere Therapeutics, up from $7.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $76.2 million in Q3 2022 and bottomed at $5.9 million in Q3 2025.
• A 5-year average of $25.1 million and a median of $10.3 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Peak annual rise in Other Non-Current Liabilities reached 626.57% in 2023, while the deepest fall reached 89.0% in 2023.
• Travere Therapeutics' Other Non-Current Liabilities stood at $9.4 million in 2022, then climbed by 9.96% to $10.3 million in 2023, then sank by 34.15% to $6.8 million in 2024, then climbed by 11.85% to $7.6 million in 2025, then grew by 23.38% to $9.4 million in 2026.
• Business Quant data shows TVTX's Other Non-Current Liabilities at $9.4 million in Q1 2026, $7.6 million in Q4 2025, and $5.9 million in Q3 2025.